Should terminally ill patients have the right to take drugs that pass phase I testing? Yes

BMJ

Volumn 335, Issue 7618, 2007, Pages 478-

  Freireich, Emil J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADVANCED CANCER; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CLINICAL TRIAL; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; DRUG USE; EVIDENCE BASED MEDICINE; EXPERIMENTAL STUDY; HUMAN; INFORMED CONSENT; INTERNET; LIFE EXPECTANCY; MEDICAL CARE; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SHORT SURVEY; TERMINALLY ILL PATIENT; NEOPLASM; NOTE; PATIENT SATISFACTION; PHASE 2 CLINICAL TRIAL;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DRUG INDUSTRY; HUMANS; NEOPLASMS; TERMINALLY ILL; PATIENT SATISFACTION;

EID: 34548626593     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.39244.451192.AD     Document Type: Article

References (4)

1. DeVita VT. Should the FDA be the doctor of last resort? Nat Clin Pract Oncol 2005; 2: 423.
2. Seeber S, Braun AH. Phase III trials in oncology: setting standards of care? Nat Clin Pract Oncol 2005; 2: 426–427.
3. Freireich EJ. The investigational new drug application–who benefits? Nat Clin Pract Oncol 2006; 3: 62–63.
4. Abigail Alliance for Better Access to Developmental Drugs.www.Abigail-Alliance.org